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Background: Spondyloarthritis (SpA) are the most common group of chronic
inflammatory rheumatic diseases affecting about 1.5% of the adult Caucasian
population. Low back pain is the most common symptom. The aetiopathogenesis
of SpA is multifactorial, with well-known genetic and environmental contributions.
Furthermore, muscle properties might also be involved in the pathophysiological process
and these could be modulated by the genetic background. Alpha-actinin-3 (ACTN3) and
Vitamin D receptor (VDR) genes are well-known genes related with muscle performance.
Our aim was to analyze four SNPs of these genes and to evaluate their influence in axial
SpA (axSpA) susceptibility, phenotype and muscle properties.
Methods: We performed a pilot study based on case-control approach involving 56
participants: 28 axSpA patients and 28 healthy controls matched by age, gender
and levels of physical activity. Clinical, epidemiological and muscle characterization
data—muscle physical properties (stiffness, tone, and elasticity), strength, mass, and
performance, were collected. Two different muscles were considered for analysis, the
Multifidus and Gastrocnemius. Four SNPs of ACTN3 (rs1815739) and VDR (rs2228570,
rs731236, and rs7975232), were selected, analyzed and correlated with clinical,
epidemiological and muscle characterization data.
Results: In total, 51 individuals (27 axSpA patients and 24 matched controls) were
eligible for further genetic analysis, 66.7% being male and with a mean age of 36 years.
Muscle physical properties, muscle strength and muscle mass were similar in both
groups; however, axSpA patients showed a decrease in muscle performance. None
of the studied SNPs were associated with disease susceptibility/phenotype, muscle
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physical properties, muscle strength or muscle mass. However, ACTN3 rs1815739 and
VDR rs2228570 were shown to be associated with muscle performance.
Conclusion: Our results suggest an association between ACTN3 and VDR
polymorphisms and muscle performance in axSpA.
Keywords: spondyloarthropathies, muscle, muscle performance, ACTN3, VDR
INTRODUCTION
Spondyloarthritis (SpA) is one of the most common groups
of chronic inflammatory rheumatic diseases, affecting about
1.5% of the Caucasian adult population (Apostolakos et al.,
2014; Costantino et al., 2018). SpA is typically characterized by
inflammation of the spine and sacroiliac joints accompanied by
pain, stiffness and in late stages, by reduced mobility. The disease
may also affect the peripheral joints, periarticular structures
(enthesitis, dactylitis), and extra-articular systems (acute anterior
uveitis, psoriasis, and inflammatory bowel diseases) (Pimentel-
Santos et al., 2012; Stolwijk et al., 2016; Costantino et al., 2018).
Entheses play a critical role in SpA ethiopathogeny and in the
normal function of the musculoskeletal system. This structure
not only allows the transmission of muscle contractile forces into
the skeletal attachment site, but also participates in the dissipation
of force from tendon into bone (Apostolakos et al., 2014).
The entheses have a unique immune microenvironment
that can be stimulated through the combination of several
factors (such as genetic predisposition, mechanical stress in
the joints, and microbiota immune activation), leading to
prostaglandin E2 release and IL-23-IL17 axis activation (Schett
et al., 2017). This phenomenon leads to an influx of innate
immune cells, promoting chronic inflammation in the entheses,
followed by mesenchymal tissues responses and osteogenesis
(Benjamin and Mcgonagle, 2001; Schett et al., 2017). In
spite of all this information the underlying pathophysiological
mechanisms for axial spondyloarthritis (axSpA) susceptibility
remain unknown (Asquith et al., 2014; Gill et al., 2015;
Van Mechelen and Lories, 2016).
The strong genetic component associated with the presence
of HLA-B27 has been validated in different populations
(Rosenbaum and Davey, 2011; Rudwaleit et al., 2011; Pimentel-
Santos et al., 2013; Costantino et al., 2018). On the other hand,
several loci and haplotypes relevant to disease susceptibility
were identified through “Genome Wide Association Studies”
(GWAS) (Sieper et al., 2009; International Genetics of Ankylosing
Spondylitis et al., 2013; Osgood and Knight, 2018). Finally,
expression studies also allowed the identification of genes
related to inflammation, cartilage, bone and muscle metabolism
(Pimentel-Santos et al., 2011). However, these studies can only
explain a small portion of disease genetic predisposition and
phenotype (Costantino et al., 2018).
In recent years, a link between biomechanical stress and axSpA
susceptibility and severity has been raised. In axSpA patients and
in animal models of the disease, the occurrence of microtrauma
related to physical activities seems to induce inflammation and
osteoproliferation within the spine (Mcgonagle et al., 2001;
Jacques et al., 2014; Ramiro et al., 2015). Another study
demonstrated an increased stiffness of the axial muscles in
patients with axSpA (Andonian et al., 2015). Conceptually,
microtrauma induced by daily activities (or by the muscle itself),
may play an essential role in disease susceptibility/severity.
Moreover, many studies support the notion that the gut
microbiota plays an important role in axSpA through alterations
of intestinal permeability, stimulation of immune responses, and
molecular mimicry (Asquith et al., 2014; Gill et al., 2015). Thus,
it is reasonable to speculate that general axSpA susceptibility
and progression may result from a combination of host genetics,
microbiota and micro-trauma. Still, how these factors interact
with each other remains largely unknown (Benjamin and
Mcgonagle, 2001; Simone et al., 2018). Further insights into
genetic factors influencing muscle properties in axSpA patients
will help unveil these complex interactions.
Human Alpha- actinin 3 (ACTN3) and Vitamin D receptor
(VDR) genes are associated with physical fitness and/or
performance and muscular efficiency (Ceglia, 2009; Rejnmark,
2011; Pickering and Kiely, 2017). ACTN3 protein is a fast-twitch-
specific isoform uniquely expressed in type-II muscle fibers,
having an important role in the generation of contractile forces at
high speeds (Pickering and Kiely, 2017). The VDR gene exhibits
different PCR-RFLP single-nucleotide polymorphisms (SNPs),
being BsmI, FokI, ApaI, and TaqI the most studied, which are
thought to be associated with higher VDR activity (Ceglia, 2009;
Hamilton, 2010; Rejnmark, 2011) or with protein function, also
changing cellular responses to therapies (Hunt et al., 2009).
Thus, the aim of the present study is to characterize
the association between ACTN3 and VDR SNPs with axSpA
susceptibility or disease characteristics, namely disease activity,
functional, and metrological assessments, and in particular, the




This pilot study enrolled 56 Caucasian individuals, of which
28 unrelated patients. All patients were previously diagnosed
with axSpA and fulfill the Assessment of Spondyloarthritis
international Society (ASAS) axSpA classification criteria
(Rudwaleit et al., 2009) and the 28 healthy controls were matched
by gender, age and level of physical activity. Cases were recruited
from a Rheumatology outpatient clinic.
Eligible axSpA participants were recruited according to
the following inclusion criteria: (1) axSpA, meeting the ASAS
classification criteria, and symptom duration under 10 years;
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(2) Age between 18 and 50 years old; (3) Non-steroidal anti-
inflammatory drugs (NSAIDs) and/or corticosteroids (equivalent
to ≤ 10 mg of prednisone), in stable doses ≥ 4 weeks before
screening was allowed; (4) Ability to provide informed consent.
The exclusion criteria were: (1) Body mass index (BMI) ≥ 35
kg/m2, (2) Previous exposure to synthetic disease-modifying
anti-rheumatic drugs (DMARDs) or biological disease-
modifying anti-rheumatic drugs (bDMARDs); (3) Current
pregnancy or breastfeeding; (4) Infection that required hospital
stay, intravenous antibiotic treatment in the previous 30 days
or oral antibiotic treatment within 14 days before screening; (5)
Neoplastic disease (except for successfully treated squamous
or basal cell carcinoma); (6) Any non-treated conditions (e.g.,
diabetes mellitus, ischemic heart disease); (7) Intra or peri-
articular and tendon sheaths injections within 28 days prior to
screening; (8) Rachis ankylosis (with syndesmophytes in all levels
from D12 to S1, on lateral spine radiograph).
The current study was submitted and approved by both
ethical committees of NOVA Medical School-Faculdade de
Ciências Médicas, Universidade NOVA de Lisboa, Portugal and
Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz,
EPE, Lisboa, Portugal. The study was conducted in accordance
with International Conference on Harmonization good clinical
practices and the Declaration of Helsinki. Voluntary written
informed consent was obtained from all subjects before starting
study procedures.
Clinical Protocol
All 56 participants were submitted to a standardized protocol
for extensive epidemiologic and muscle characterization. Physical
activity was assessed according to the International Physical
Activity Questionnaire (IPAQ) (Craig et al., 2003). The axSpA
patients were also clinically evaluated (including Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing
Spondylitis Functional Index (BASFI), disease duration, therapy).
Additionally, Bath Ankylosing Spondylitis Metrology Index
(BASMI) and myofascial characterization were performed by a
single investigator (FPS), using different approaches:
(1) Muscle physical properties (stiffness, tone, and elasticity),
assessed by a non-invasive device, the MyotonPro R©,
focusing on axial/torso (multifidus and longissimus
dorsi) and on peripheral/lower limbs (gastrocnemius)
muscles. The participants were in a prone position and
measurements were taken after a 10 min rest.
(2) Muscle strength, measured using the Lafayette Manual
Muscle Testing System for torso extension and lower limb
extension; global strength evaluated through 5 times Sit-to-
Stand test (STS5) (Cruz-Jentoft et al., 2019).
(3) Muscle Mass, assessed by bioimpedance, using
direct segmental 8-point multifrequency bioelectric
impedance analysis (InBody770, InBody Co., Ltd., Seoul,
South Korea).
(4) Muscle performance, assessed by 60 s Sit-to-Stand test
(ST60) and Gait speed (Cruz-Jentoft et al., 2019),
using a 3D full-body kinematic model (Kinetikos R©
Coimbra, Portugal).
Due to the absence of already established reference values
for some variables related to physical muscular characteristics
(stiffness, decrement/inverse of elasticity, tone), we have defined
categories (low, intermediate and high) for the whole population
group (for details see Supplementary Material), without taking
into account the differences between genders because of
the reduced sample size. Clinical variables were categorized
according to the following cut offs in “not active/active disease”
(BASDAI < 4, BASDAI ≥ 4), “Low/high functional ability”
(BASFI < 4, BASFI ≥ 4) and low/high reduction in spinal range
of motion (BASMI < 3, BASMI ≥ 3).
Genotyping
Genomic DNA from all participants was isolated from
peripheral blood samples using PureLinkTM Genomic DNA
Mini Kit (Invitrogen) according to the manufacturer’s protocol
instructions for blood lysates.
All samples were screened and genotyped for ACTN3 and
VDR genes polymorphisms: R557X (rs1815739) and ApaI
(rs7975232), FokI (rs2228570), TaqI (rs731236), respectively, that
have previously been associated with muscle performance in
both men and women.
All SNPs studied (Table 1) were previously selected
considering the Minor Allele Frequency (MAF) above or
equal to 5% for European Caucasian population (HapMap CEU).
SNPs under study belong to several parts of the gene: regulatory
region, coding region or non-coding region.
The genotyping analysis was performed by quantitative
polymerase chain reaction (qPCR) carried out on a 96-well QS5
Real-Time PCR (RT-PCR) System (Applied Biosystems; Thermo
Fisher Scientific, Inc., Waltham, MA, United States), following
the manufacturer’s instructions with the use of the commercially
available TaqMan R© SNP Genotyping Assays (Applied Biosystems)
detailed in Table 1. To confirm genotyping and ensure accurate
results, inconclusive samples were reanalyzed, and genotyping
was repeated in 10–15% of randomly chosen samples, with
100% concordance.
Statistical Analysis
Data analysis was performed using the Statistical Package for
the Social Sciences for Windows 22.0 version (SPSS, Inc.). All
genotypes were coded accordingly in order to proceed with the
statistical analysis. The analysis of Hardy-Weinberg frequencies
for all alleles present in patients’ populations was carried out
using exact probability tests available using the SNPStat software1
(Sole et al., 2006).
Participants’ demographic, clinical, and biomechanical
characteristics were described and compared between healthy
individual and patients with axSpA, using Chi-Square (χ2)
for discrete data and Wilcoxon-Mann-Whitney-test for
non-parametric continuous data.
Since this is not a conclusive final study, but an exploratory
one on the role of selected polymorphisms in the ACTN3 and
VDR genes, and the data to be obtained should be looked at as
1http://bioinfo.iconcologia.net/SNPstats
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TABLE 1 | Identification of all genetic variants included in the study.
Gene dsSNP ID (rs) SNP Variant type A.A residue Context sequence [VIC/FAM]
ACTN3 rs1815739 R577X Non-sense R/STOP CAAGGCAACACTGCCCGAGGCTGAC[T/C]GAGAGCGAGGTGCCATCATGGGCAT
VDR rs2228570 FokI Missense K/R GGAAGTGCTGGCCGCCATTGCCTCC[A/G]TCCCTGTAAGAACAGCAAGCAGGCC
VDR rs731236 TaqI Silent I/I TGGACAGGCGGTCCTGGATGGCCTC[A/G]ATCAGCGCGGCGTCCTGCACCCCAG
VDR rs7975232 ApaI Intron – AAGGCACAGGAGCTCTCAGCTGGGC[A/C]CCTCACTGCTCAATCCCACCACCCC
The bold values refers to the nucleotide change and the correspondence with the correspondent fluorocrome.
proof of concept, the Bonferroni adjustment was deemed as not
necessary as it is too conservative.
Logistic regression was used to estimate the risk of each muscle
property modification when associated with each genotype:
risk estimates were calculated under the codominant model
and expressed as crude odds ratios (OR) and corresponding
95% confidence intervals (CI). Association between SNPs and
the quantitative variables BASDAI, BASFI, BASMI, stiffness,
decrement/inverse of elasticity, tone and strength were tested
by linear regression. Results were considered significant when
the corresponding two-tailed p-values were < 0.05. The most
common homozygous genotype was considered the reference




Even though the study started with 56 enrolled participants,
in equal number of controls and patients, due to missing data
in some physical measures and in individuals’ polymorphisms
identification, the total sample population ended up comprising
51 individuals (27 axSpA patients and 24 controls). The axSpA
patients, 66.7% male with a mean age of 36 ± 7 years old and
a mean of 7.0 ± 0.9 years of disease duration. From the total of
patients, 80.8% were HLA-B27 positive, 18.5% had active disease
(BASDAI ≥ 4) and 14.8% presented high functional impairment
(BASFI > 4). The majority of patients did not exhibit reduction
in mobility (88.9% had BASMI < 3). There was no difference
between patients and controls in terms of age, gender, level of
physical activity and body mass.
Baseline characteristics are shown in detail, in Table 2, where
all data comparison between patients and controls can be found.
Clinical Data—Muscle Characteristics
Analysis
We recorded and analyzed the results obtained from lumbar
paravertebral muscle (Multifidus muscle) physical properties,
namely: Muscle tonus (M.F); Muscle decrement, i.e., the inverse
of elasticity (M.D) and Muscle stiffness (M.S). The regression
analysis was performed individually for each characteristic (crude
analysis) (Table 3).
No significant differences in muscle physical properties,
muscle strength (ST5) and muscle mass were identified between
patients and controls. However, it seems that patients tend to
express higher levels of stiffness in multifidus muscle (trunk)
(Table 3). Muscle performance, measured by ST60 and gait
speed, was significantly reduced in patients, compared to controls
(p < 0.05).
Genotyping and Individual Susceptibility
Analysis
After genotyping analysis, the SNPs distribution was performed
and their genetic contribution to disease susceptibility was
evaluated (Table 4). To perform the correlations, we deemed
TABLE 2 | Study population characterization. Cases group (n = 27) and Healthy
control group (n = 24).
Characteristics Cases,
n (%)
Mean ± SD Controls,
n (%)
Mean ± SD p-value*
Age
0–29 3 (11.1) 4 (16.7)
30–39 14 (51.9) 36.8 ± 7.1 10 (41.7) 36.8 ± 7.7
40–50 10 (37.0) 10 (41.7) 0.728
Gender
Male 18 (66.7) – 15 (62.5) –
Female 9 (33.3) 9 (37.5) 0.756
Physical Activity level
Low 22 (81.5) – 21 (87.5) –
High 5 (18.5) 3 (12.5) 0.555
HLA-B27
Positive 21 (80.8)
Negative 5 (19.2) – – –
Not available 1 –
Body height (cm) – 170.4 ± 7.4 – 171.1 ± 8.8
Body weight (kg) – 75.9 ± 12.7 – 71.8 ± 12.9
BMI
Low weight 1 (4.2) 1 (4.3)
Normoponderal 11 (45.8) 13 (56.5) 24.5 ± 3.7 0.410
Overweight 7 (29.2) 26.2 ± 4.3 8 (34.8)
Obesity 5 (20.8) 1 (4.3)
Not available 3 1
BASDAI
<4 22 (81.5) 3.0 ± 2.0 – – –
≥4 5 (18.5)
BASFI
≤4 23 (85.2) 2.2 ± 2.7 – – –
>4 4 (14.8)
BASMI
<3 24 (88.9) 1.1 ± 1.3 – – –
≥3 3 (11.1)
*p-value determined by χ2-test.
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p-value* ORcrude (95% CI)
Muscle physical properties
Muscle tonus#
Low 6 (22.2) 9 (37.5) 1.000 (reference)
Intermediate 9 (33.3) 10 (41.7) 0.185 1.350 (0.343–5.315)
High 12 (44.4) 5 (20.8) 3.600 (0.829–15.628)
Muscle decrement#
Low 6 (22.2) 9 (37.5) 1.000 (reference)
Intermediate 12 (44.4) 7 (29.2) 0.406 2.571 (0.640–10.338)
High 9 (33.3) 8 (33.3) 1.687 (0.414–6.878)
Muscle stiffness#
Low 5 (18.5) 11 (45.8) 1.000 (reference)
Intermediate 12 (44.4) 6 (25.0) 0.099 4.400 (1.041–18.599)†
High 10 (37.0) 7 (29.2) 3.143 (0.751–13.159)
Muscle strength
ST5
Normal 25 (92.6) 22 (100.0) 0.192 N.D.
Reduced 2 (7.4) 0 (0.0)
Muscle mass
Muscle mass
Low 1 (4.2) 22 (100.0)




Low 9 (33.3) 0 (0.0) 0.008 N.D.
Intermedium 8 (29.6) 7 (31.8)
High 10 (37.0) 15 (68.2)
Gait speed
Good 6 (27.3) 12 (57.1) 0.047 1.000 (reference)
Low 16 (72.7) 9 (42.9) 3.556 (0.993–12.733)‡
*p- value determined by χ2-test; #Swiss reference values were used. ‡borderline
effect (P-value = 0.051). BMI (Body mass Index); ST5 (5 Times Sit-to-Stand Test);
ST60 (60 s Sit-to-Stand Test). #Categorization parameters. †p-value = 0.044. The
bold values refers to values satistical significants.
it important to verify if the four SNPs were in Hardy-
Weinberg Equilibrium (HWE). All the populations followed
the Hardy-Weinberg Equilibrium (HWE), except for TaqI SNP
(p-value = 0.021).
Considering that three SNPs from the same gene (VDR) were
analyzed, we also evaluated the possibility of establishing an
haplotype. However, the allele combination obtained for our
populations did not reveal a statistically relevant combination
to be correlated with disease susceptibility. After a multiple-
SNP analysis, the results showed the existence of Linkage
Disequilibrium between ApaI and TaqI SNPs from VDR
(D’ = 0.9382, p-value ≤ 0.001).
Another question we wanted to address was related to the
potential role of ACTN3 and VDR genes polymorphisms in
the etiology of the disease evaluating the risk magnitude. The
genotypic frequencies were determined for both groups and for
all SNPs under study.
TABLE 4 | Genotype distribution between axSpA patients and controls, for
ACTN3 and VDR polymorphisms: rs1815739 (R577X); rs2228570 (FokI),
rs731236 (TaqI), and rs7975232 (ApaI).
Genotype Cases n (%) Controls n (%) p-value* ORa (95% CI)
ACTN3 R577X
C/C 8 (30.8) 6 (25.0) 1.000 (reference)
C/T 15 (57.7) 12 (50.0) 0.463 0.375 (0.066–2.145)
T/T 3 (11.5) 6 (25.0) 0.938 (0.255–3.449)
C/T + T/T 18 (69.2) 18 (75.0) 0.750 (0.216–2.602)
VDR—FokI
A/A 4 (15.4) 2 (8.3) 1.000 (reference)
A/G 12 (46.2) 16 (66.7) 0.339 0.375 (0.059–2.397)
G/G 10 (38.5) 6 (25.0) 0.833 (0.115–6.013)
A/G + G/G 22 (84.6) 22 (91.7) 0.500 (0.083–3.017)
VDR—TaqI
A/A 11 (42.3) 7 (30.4) 1.000 (reference)
A/G 7 (26.9) 9 (39.1) 0.599 0.495 (0.126–1.945)
G/G 8 (30.8) 7 (30.4) 0.727 (0.181–2.914)
A/G + G/G 15 (57.7) 16 (69.6) 0.597 (0.183–1.943)
VDR—ApaI
C/C 7 (28.0) 3 (12.5) 1.000 (reference)
C/A 9 (36.0) 10 (41.7) 0.400 0.351 (0.070–1.761)
A/A 9 (36.0) 11 (45.8) 0.386 (0.076–1.959)
C/A + A/A 18 (72.0) 21 (87.5) 0.367 (0.083–1.633)
*p-value χ2-test. Abbreviations: a ORs and 95% CI for specific categories were
calculated using logistic regression models; OR, odds ratio; CI, confidence interval.
According to the results obtained, the studied SNPs
did not seem to be associated with an increased risk of
axSpA susceptibility.
In addition, axSpA clinical parameters (BASDAI, BASFI, and
BASMI) were also measured in the patient population and
the association with the allelic distribution for each SNP was
investigated (Table 5). ACTN3 and VDR polymorphisms did not
markedly influence axSpA disease activity, physical function or
severity, as measured by BASDAI, BASFI, and BASMI.
We hypothesize how relevant the genetic background might
be to explain muscle properties (physical-stiffness, tone, elasticity;
strength; mass) and in particular physical performance (ST60
and Gait Speed), where statistically significant differences
between patients and controls were registered. To understand
the hypothetical effect of single SNP in these parameters, we
applied the logistic regression model adjusted to the presence
of the genetic component; the results are presented in the table
below (Table 6).
Data shown refers only to ACTN3 and VDR Fok1
polymorphisms, since the logistic regression of the other
two SNPs did not show statistically significant results.
DISCUSSION
This pilot study, involving 27 young axSpA patients with short
disease duration, has not shown any difference in muscle physical
properties, global muscle strength or mass compared to controls.
However, a reduction in muscle performance assessed by two
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TABLE 5 | Clinical characteristics across ACTN3 and VDR genes polymorphisms.
SNPs BASDAI BASFI BASMI














C/C 6 (28.6) 2 (40.0) 6 (27.3) 2 (50.0) 8 (34.8) 0 (0.0) 6 (25.0)
C/T 12 (57.1) 3 (60.0) 0.700 13 (59.1) 2 (50.0) 0.633 12 (52.2) 3 (100.0) 0.398 12 (50.0)
T/T 3 (14.3) 0 (0.0) 3 (13.6) 0 (0.0) 3 (13.0) 0 (0.0) 6 (25.0)
VDR—FokI
A/A 3 (14.3) 1 (20.0) 3 (13.6) 1 (25.0) 4 (17.4) 0 (0.0) 2 (8.3)
A/G 9 (42.9) 3 (60.0) 0.534 9 (40.9) 3 (75.0) 0.247 9 (39.1) 3 (100.0) 0.188 16 (66.7)
G/G 9 (42.9) 1 (20.0) 10 (45.5 0 (0.0) 10 (43.5) 0 (0.0) 6 (25.0)
VDR—TaqI
A/A 9 (42.9) 2 (40.0) 11 (50.0) 0 (0.0) 10 (43.5) 1 (33.3) 7 (30.4)
A/G 5 (23.8) 2 (40.0) 0.810 5 (22.7) 2 (50.0) 0.323 6 (26.1) 1 (33.3) 0.886 9 (39.1)
G/G 7 (33.3) 1 (20.0) 6 (27.3) 2 (50.0) 7 (30.4) 1 (33.3) 7 (30.4)
VDR—ApaI
C/C 6 (28.6) 1 (25.0) 7 (31.8) 0 (0.0) 6 (26.1) 1 (50.0) 3 (12.5)
C/A 7 (33.3) 2 (50.0) 0.692 8 (36.4) 1 (33.3) 0.415 9 (39.1) 0 (0.0) 0.528 10 (41.7)
A/A 8 (38.1) 1 (25.0) 7 (31.8) 2 (66.7) 8 (34.8) 1 (50.0) 11 (45.8)
*p-value χ2-test; BASDAI < 4, “no active disease”; BASDAI ≥ 4 “active disease”; BASFI < 4 “low functional repercussion”; BASFI ≥ 4 “high functional repercussion,” and
BASMI < 3, low reduction, BASMI ≥ 3, high reduction in movement amplitude.
different approaches, ST60 and Gait speed, was found. Even
using a small participant’s sample, the overall results allowed
us to generate relevant data on disease susceptibility evidencing
low physical performance in spondiloarthritis patients. Thus, we
considered interesting to examine if genes associated with muscle
performance, such as ACTN3 and VDR, might contribute to
explain such differences.
As expected, due to our selection criteria, both groups
(SpA patients and controls) are largely similar, regarding age,
gender, levels of physical activity. When analyzing disease
characteristics, the majority of patients exhibit low disease
activity, low functional and low metrological repercussion. Most
of our patients are HLA-B27 positive (80.8%), which is in line
with the percentages already found for the Portuguese population
(Pimentel-Santos et al., 2012). Due to the small size of our study
population and low number of female individuals, we did not take
into account possible gender differences in any of our analysis.
In this study, we selected several SNPs of well-known genes—
ACTN3 (Ma et al., 2013; Pratt et al., 2019) and VDR (Pratt
et al., 2019)—related with muscle performance to evaluate
their influence in axSpA susceptibility, axSpA phenotype and
in muscle properties. In this context, we were interested in
studying these genetic variants in the axSpA context looking
for the variants related with low muscle performance and
simultaneously evaluate any association with muscle physical
properties, strength, and lean mass. This would represent an
additional method to identify patients that might benefit from a
program of physical exercise and to the identification of the best
modalities to be used in clinical practice.
In our study, we demonstrate that ACTN3 and VDR are
not significantly associated with either susceptibility to axSpA
or measures of its activity, disability or severity, as measured
by BASDAI, BASFI, and BASMI, respectively. Indeed, no
association has been identified in GWAS between these genes
and SpA (Australo-Anglo-American Spondyloarthritis et al.,
2010; International Genetics of Ankylosing Spondylitis et al.,
2013). Nevertheless, some VDR polymorphisms have been linked
to some musculoskeletal diseases, such as idiopathic scoliosis
susceptibility or curve severity, herniation and spinal tissues
degeneration and rheumatoid arthritis (Saad et al., 2015; Di
Spigna et al., 2016; Vieira et al., 2018; Li et al., 2019).
No association was established between the studied SNPs and
muscle physical properties, namely stiffness, tone or elasticity. To
the best of our knowledge, this association was never studied.
Again, no association for overall strength (ST5) was registered
in our cohort. However, in several previous studies, ACTN3
577R allele and VDR were associated with higher levels of
strength. The rs540874 polymorphism of ACTN3 gene was
associated with the muscle function of lower limb (women
with the G allele were likely to have higher strength compared
with the ones with A allele) but not with the higher limb, in
postmenopausal women. Interestingly, in the same study, the
improvement of muscle strength after an intervention (exercise
and Vitamin D supplementation) was possibly correlated with
rs540874, rs618838, and rs2229456 polymorphisms (Xue et al.,
2018). A significant association between VDR genotype and
quadriceps (23% difference) and grip (7% difference) strength
was observed in non-obese elderly women (Geusens et al., 1997).
The analysis of these genetic markers regarding lean muscle
mass did not show, again, any difference between both groups.
It is well-known that genetic factors account for approximately
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ORs and 95% CI for specific categories were calculated using logistic regression
models; OR, odds ratio; CI, confidence interval. ap-value = 0.051; bp-
value = 0.043; cp-value = 0.047. The bold values refers to values satistical
significants.
50-80% of inter-individual variation in lean body mass, with
impacts detected on both “training-naïve” muscle mass and
its growth response (Puthucheary et al., 2011). Indeed, these
genes have been found to contribute to variation in lean body
mass and bone mass density, contributing to understanding the
molecular bases of sarcopenia and osteoporosis (Tan et al., 2012;
Gonzalez-Mercado et al., 2013; Cho et al., 2017; Scimeca et al.,
2018). However, in one study involving older Caucasian men,
whole body and thigh non-skeletal lean mass were independent
of ACTN3 R/X polymorphisms (Mccauley et al., 2010). In
contrast, VDR expression decreases with age and VDR genotype
seems to be associated with fat-free mass in elderly men and
women (Puthucheary et al., 2011). Differences in populations’
characteristics, study methodologies and reduced number of
participants (underpowered studies) to detect genes with small
effects, potentially lead to discrepancies between results.
This study has shown a clear reduction in axSpA muscle
performance without changes in muscle physical properties,
strength, and mass. This observation allows us to speculate
about a possible muscle dysfunction. As genetics has a strong
influence in overall axSpA susceptibility, it is of main interest
to investigate a possible genetic base to explain this impairment
in muscle performance. Our results indicate that ACTN3 R577X
and VDR Fok1 SNPs might influence Gait Speed [OR, 3.911;
95% CI (1.044–14.658) and OR, 3.785; 95% CI (1.025–13.982)].
Several studies have shown an association of these variants
on muscle performance. In 2003, Yang and colleagues (Yang
et al., 2003) demonstrated a significant association between
ACTN3 genotype and athletic performance. They found that both
male and female elite sprint athletes have significantly higher
frequencies of the 577R allele compared to controls. Later on,
several papers consistently reported a strong association between
RR genotype and elite power performance (Paparini et al., 2007;
Papadimitriou et al., 2008; Eynon et al., 2009; Chiu et al., 2011;
Ma et al., 2013). Similar evidence was documented for VDR
polymorphisms (Micheli et al., 2011; Puthucheary et al., 2011). In
elite Italian soccer players, an interaction of two polymorphisms
(ACE and ACTN3) predicted explosive leg-muscle strength,
however, the contribution of genetic factors was only 23.92%
(Massidda et al., 2012).
The genotype distribution of all SNPs was in HWE, except
for the TaqI polymorphism (p = 0.021), suggesting the influence
of genetic drift due to the small population size. Furthermore,
we also evaluated the possibility to establish a specific haplotype
for VDR gene polymorphisms, however, no haplotype was
identified as relevant. Our results allowed us to identify Linkage
Disequilibrium between ApaI and TaqI SNPs, indicating that
both are segregated together. This corroborates some studies
(Hamilton, 2010) and means that both SNPs are always
transmitted in block (Cieslinska et al., 2018) (data not shown),
even though it was not possible to identify a risk haplotype for
our population. Despite the literature revealing that VDR SNPs
constitute a haplotype, due to their proximity, we could not
confirm those reports (Hunt et al., 2009).
To our knowledge, this pilot study is the very first including a
genetic susceptibility analysis for muscle properties in the axSpA
context. Overall, our results suggest an association between
ACTN3 and VDR polymorphisms and muscle performance in
the axSpA context. This opens the door to a better stratification
of patients regarding exercise programs, but also to identify
other candidate genes that might help to characterize the genetic
background of the disease.
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